U.S. FDA Approves HYRNUO® (sevabertinib) for Previously Treated Patients with HER2-Mutated Locally Advanced or Metastatic Non-Squamous NSCLC ...
The FDA has approved Hyrnuo for some with locally advanced or metastatic non-squamous non–small cell lung cancer with ...
Just a few months after Boehringer Ingelheim broke into the oncology space with the first drug that can target a rare tumor ...
Bayer (BAYZF) stock is in focus as the FDA grants accelerated approval for the company's tumor drug Hyrnuo in non-squamous ...
FDA grants accelerated approval to Bayer's Hyrnuo and full approval to Amgen's Imdelltra, expanding treatment options for ...
Berlin: Bayer has received accelerated approval from the U.S. Food and Drug Administration (FDA) for HYRNUO ...
The U.S. Food and Drug Administration said on Wednesday that it has approved Bayer's drug for patients with a form of lung ...
This indication is approved under accelerated approval based on objective response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification ...
In patients naïve to HER2-targeted therapy, the objective response rate was 71% with a median duration of response of 9.2 months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback